If you’ve spent any time reading about longevity, you’ve probably noticed something strange: the smartest people in the field can’t seem to agree on what to do.

Peter Attia tells you to lift heavy, eat plenty of protein, build the biggest muscle reserve you can, and basically prepare your body for the hard last decade of life.

Valter Longo tells you to fast periodically, restrict protein in middle age, lean toward plants, and treat fasting as the most powerful intervention you have.

David Sinclair tells you aging itself is reversible and gene therapy will eventually let us reset it. His company’s first human trial is recruiting now.

These are not minor disagreements at the edges. They lead to genuinely different daily habits and very different long-term bets. They’re also, surprisingly, all defensible from the same body of research. Same evidence, different conclusions.

That’s worth understanding, because the disagreement isn’t really about the science. It’s about a deeper question: what should you actually optimize for?

A little background

The mechanism behind all of this is covered in the previous two articles in this series. The autophagy piece walks through cellular cleanup. The mTOR vs AMPK piece explains the two switches that everyone is fighting over. You don’t need to read those to follow this one, but if you find yourself wondering why fasting matters or why protein affects mTOR signaling, that’s where the wiring lives.

In short: your cells have two opposing pathways. mTOR is the build-and-grow signal. AMPK is the conserve-and-clean signal. Almost every longevity intervention works by tipping the balance between them. The fight between Attia, Longo, and Sinclair is, at the molecular level, a fight about how much to tip the balance and in which direction.

Where they actually agree

Before getting into the fight, it’s worth saying how much these three actually share. Probably more than the discourse suggests.

All three are emphatic that exercise matters. All three care a lot about sleep. All three think ultra-processed food, smoking, excess alcohol, and chronic stress accelerate everything bad. All three are skeptical of most “longevity supplements” sold online. All three think visceral fat is dangerous. All three accept that some form of dietary moderation or periodic restriction is probably beneficial.

The disagreement is at the margins. But the margins are where the day-to-day decisions live.

The Resilience theory

Attia’s frame, laid out most fully in his book Outlive, starts from a clear-eyed observation about what actually kills people in developed countries. The “four horsemen” are cardiovascular disease, cancer, neurodegeneration, and metabolic disease (type 2 diabetes and its complications). Plus a fifth he treats almost as a separate category: sarcopenia, frailty, and the cascade of falls, fractures, and dependence that defines a bad last decade.

From this frame, the goal isn’t to slow aging itself. The goal is to prepare your body to absorb decline. Strength, muscle mass, VO2max, bone density, cognitive reserve, and metabolic flexibility are buffers. The bigger the buffer at age 60, the more decline it takes to push you into frailty at age 80.

The human evidence for this view is strong. Grip strength predicts mortality. Cardiorespiratory fitness predicts mortality more strongly than almost any other modifiable factor. Muscle mass loss in older adults predicts not just death but disability and loss of independence. These are not animal-model speculations. They’re observational findings repeated in large human cohorts over decades.

The practical implications are direct. Train hard, especially with resistance work. Eat plenty of protein (Attia recommends about 1 gram per pound of bodyweight per day, on the high end of mainstream advice), spread across meals to drive muscle protein synthesis. Build VO2max with aerobic work. Sleep well. Manage the four horsemen aggressively with whatever tools work, including drugs.

The underlying bet: we can’t reliably slow aging yet, so spend your energy building the biggest possible buffer while you still have the years to do it. Prepare your body for a hard landing, because a hard landing is coming whether you like it or not.

The Slowdown theory

Longo’s frame, developed across decades of research and laid out in The Longevity Diet and his academic papers, starts from a different observation. Aging itself is the upstream driver of every major disease that kills people. Cardiovascular disease, cancer, neurodegeneration, and metabolic disease all become dramatically more common with age. If you could slow the underlying process, you’d push back all of them at once.

The evidence for slowing aging in animals is, equally honestly, strong. Caloric restriction extends lifespan across species. Lower-protein diets extend lifespan in mice. Rapamycin extends lifespan in mice. Periodic fasting and fasting-mimicking diets produce favorable changes in human biomarkers. These findings converge on a small set of pathways (mTOR, IGF-1, AMPK, autophagy) that look like real levers on aging.

The practical implications are very different from Attia’s. Longo recommends moderate protein in middle age (around 0.8 g/kg of bodyweight, lower than what builds maximum muscle), with a U-shaped curve that goes back up after age 65 or 70 to protect against sarcopenia. He recommends a 5-day fasting-mimicking diet several times a year, which produces metabolic and biomarker changes that mimic longer fasts without the full muscle-loss penalty. He recommends mostly plant-based eating with some fish. He’s openly skeptical of constantly high-protein intake because of the chronic mTOR signaling implications.

The underlying bet: we can slow aging meaningfully with tools we already have, and chronic mTOR activation from constant high-protein eating is a real cost paid in exchange for short-term muscle benefits. Don’t trade speculative anti-aging mechanism for visible bicep.

The most ambitious version: reversal

Sinclair sits in the slowdown camp but at its most ambitious edge. His view, developed in the Information Theory of Aging, is that aging isn’t just a process of accumulating damage. It’s a loss of epigenetic information, specifically the chemical tags that tell each cell what kind of cell to be and how to behave. Restore the information, restore youthful function.

This is more than a theory. Sinclair’s group showed in 2020 that delivering three of the four Yamanaka reprogramming factors (called OSK) to the eyes of mice restored vision in older animals and in mice with optic nerve injury. The mechanism isn’t replacing damaged cells; it’s resetting existing cells to a younger functional state. Follow-up work in non-human primates was successful. In January 2026, the FDA cleared a Phase 1 trial of this approach in humans, run by Life Biosciences, the biotech Sinclair co-founded. The therapy is called ER-100, and the trial will treat patients with glaucoma and a kind of optic-nerve stroke called NAION. First results are expected late 2026 or early 2027.

Sinclair has been explicit that vision is just the starting point. If reprogramming works in retinal cells, the same approach should generalize. His longer bet is that within a decade or two we’ll have therapies that systemically reverse cellular aging.

If he’s right, the whole framework of this article changes. Why train hard to build buffers if you can reset your cells to a younger state every few years? If he’s wrong, his bet will look like the hubris that distracted a generation of biohackers from doing the basics.

Where they actually disagree

The big disagreements come down to three:

Protein. Attia wants you to eat a lot of it, frequently, especially as you age. Longo wants less, especially in middle age, with a plant lean. Sinclair is broadly aligned with Longo but less prescriptive. The split is about whether the muscle-building benefits of high protein are worth the chronic mTOR activation that comes with them. Attia: yes, obviously, because muscle in your 70s is what matters. Longo: no, because chronic mTOR activation accelerates aging itself.

Fasting. Attia has become publicly more skeptical of fasting beyond its role as a tool for caloric restriction, with concerns about muscle loss during extended fasts. Longo built his career on it. The fasting-mimicking diet is essentially his signature intervention. Same data, different interpretation: Attia weights the muscle-loss cost heavily; Longo weights the autophagy and metabolic reset benefits.

Rapamycin. Attia uses it himself but has been cautious in public commentary, especially after the recent RAPA-EX-01 trial covered in the mTOR article. Longo’s camp tends to see it as one of the more promising drug tools. Sinclair has generally been bullish.

There’s a smaller but real disagreement about muscle mass itself. For Attia, building muscle is the point. For Longo, muscle matters as protection against frailty but isn’t worth pursuing if it requires the kind of constant high-protein eating that compromises the underlying anti-aging mechanism. They’re not even optimizing for the same thing.

The first real data

The RAPA-EX-01 trial, covered in detail in the mTOR article, is the first piece of head-to-head evidence in this fight. Older adults given weekly rapamycin alongside an exercise program adapted worse than placebo. Both groups improved, but the rapamycin group improved less. Every secondary endpoint pointed the same direction.

This isn’t a knockout punch. The trial was small (40 people), short (13 weeks), and focused on muscle outcomes rather than mortality. But it’s the first real signal that the slowdown camp’s most-discussed drug may directly interfere with the resilience camp’s most-loved outcome. The two bets weren’t supposed to be in direct conflict. They might be.

The asymmetric risk argument

Here’s where this article lands.

The three camps don’t carry equal evidence weight. Attia’s pillars rest on decades of human epidemiology showing that muscle, fitness, sleep, and metabolic health predict mortality and quality of life. Longo’s interventions are supported by extensive animal work plus some human RCTs on biomarkers, but not by long-term human mortality data. Sinclair’s reprogramming is essentially pre-clinical, with one Phase 1 trial about to read out.

Different camps, different rungs on the evidence ladder.

The risks are also asymmetric. If Attia is right and you followed Longo, you may have arrived at your 70s frailer than you needed to be. If Longo is right and you followed Attia, you may have missed some hypothetical extra years of life. Frailty and dependence in your 70s and 80s is a known, common, devastating failure mode. Missing out on speculative life extension is a much softer cost.

So given current evidence: Attia’s approach is the safer bet. Not because Longo and Sinclair are wrong (they may not be), but because the cost of betting wrong on their side is higher than the cost of betting wrong on his.

This doesn’t mean dismissing the slowdown camp. It means treating their interventions as bets worth tracking, not defaults worth adopting. If you want to do periodic fasting, fine. If you want to try the fasting-mimicking diet once or twice a year, fine. But these are options on top of the boring foundation, not replacements for it.

What would change this

The asymmetric risk calculation depends on the current state of evidence. That state could shift. A few things to watch over the next 2 to 3 years:

Sinclair’s Phase 1 readout. If ER-100 produces meaningful vision improvement in humans with a clean safety profile, the case for reprogramming as a real intervention becomes much stronger. Failure or significant safety problems would set the field back substantially.

Larger rapamycin trials. RAPA-EX-01 was small. More trials are coming, and a larger study with longer follow-up could either confirm the muscle-adaptation concern or show that different dosing patterns avoid it.

Long-term FMD data. Longo’s group has good short-term biomarker data on the fasting-mimicking diet. Long-term mortality data, if it ever arrives, would dramatically change the picture.

Validated longevity biomarkers. Right now we can’t directly measure whether an intervention is slowing your aging. If epigenetic clocks or multi-omic aging scores become reliable enough to act on, the whole field becomes more empirical and a lot less ideological. (The next piece in this series goes into exactly why they aren’t reliable enough yet.)

If a few of these go the slowdown camp’s way, the conclusion of this article changes. For now, it doesn’t.

A word of caution

Most people reading this aren’t actually choosing between Attia and Longo. They’re choosing between training and not training, between cooking and ordering in, between 7 hours of sleep and 5, between real food and processed food. The marginal benefit of getting these right dwarfs the marginal benefit of being on the right side of an unresolved scientific debate.

The longevity discourse can become a way to avoid the boring stuff. Reading another podcast transcript about rapamycin protocols is easier than going to bed at 10 PM. Optimizing your supplement stack is easier than going to the gym four times a week. The fight at the top of the field is interesting, but it’s downstream of the question of whether you’re doing the things all three camps agree on.

The honest version of this whole article: if you’re doing the basics, the bet you’re making is probably going to matter less than you think. If you’re not doing the basics, the bet you’re making doesn’t matter at all.

---

References

1. Attia, P., Gifford, B. (2023). Outlive: The Science and Art of Longevity. Harmony. https://peterattiamd.com/outlive-book/
2. Longo, V.D. (2018). The Longevity Diet. Avery. https://www.valterlongo.com/the-longevity-diet-book/
3. Wei, M., Brandhorst, S., Shelehchi, M., et al. (2017). Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science Translational Medicine, 9(377). https://www.science.org/doi/10.1126/scitranslmed.aai8700
4. Yang, J.-H., Hayano, M., Griffin, P.T., et al. (2023). Loss of epigenetic information as a cause of mammalian aging. Cell, 186(2), 305–326. https://www.cell.com/cell/fulltext/S0092-8674(22)01570-7
5. Lu, Y., Brommer, B., Tian, X., et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588, 124–129. https://www.nature.com/articles/s41586-020-2975-4
6. Life Biosciences (January 2026). FDA Greenlights First Human Trial of Epigenetic ‘Rejuvenation’ Therapy for Vision Loss. https://www.biopharmatrend.com/news/fda-greenlights-first-human-trial-of-epigenetic-rejuvenation-therapy-for-vision-loss-1483/
7. Stanfield, B., Leroux, B., Kaeberlein, M., Jones, J., Lucas, R. (2026). Exercise and weekly sirolimus (rapamycin) in older adults: RAPA-EX-01 randomised, double-blind, placebo-controlled trial. Journal of Cachexia, Sarcopenia and Muscle, 17(2), e70274. https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70274
8. Attia, P., Yeater, T., Rae, M. (May 2, 2026). Disappointing results from the first rapamycin-plus-exercise trial. https://peterattiamd.com/rapamycin-plus-exercise-trial/